Epigenica AB Secures $2.2M to Accelerate the EpiFinder Revolution in Epigenetic Research

Epigenica AB is thrilled to announce a significant funding milestone, having raised 2,200,000 to accelerate its pioneering efforts in epigenetic research. As a life sciences technology company at the forefront of innovation, Epigenica has harnessed its revolutionary EpiFinder platform to redefine how researchers approach epigenetic studies. This infusion of capital will be strategically directed toward enhancing and expanding the capabilities of the EpiFinder platform, enabling even more comprehensive, high-throughput profiling that meets the diverse needs of biomedical research, drug discovery, precision medicine, diagnostics, and therapeutics for aging and longevity. The company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP) underpins this cutting-edge platform, marking it as the first commercial kit of its kind and offering unparalleled speed, scalability, and cost-efficiency in epigenetic analysis. With this fresh injection of funds, Epigenica is set to further develop its portfolio of products, providing researchers with versatile options tailored to various depths of detail and accommodating an array of starting materials. The investment will facilitate ongoing research and development, helping to refine the technology for broader applications while also expediting the launch of new tools that can drive the next wave of discoveries. Additionally, the funding will support initiatives aimed at fortifying partnerships with research institutions and pharmaceutical companies globally, thereby reinforcing Epigenica’s commitment to advancing human health through scientific innovation. This strategic milestone not only underscores the company’s leadership in epigenetics but also motivates Epigenica to continue its mission of empowering researchers to unveil the complexities of epigenetic regulation with unprecedented accuracy and efficiency.